Biogen Faces Multiple Analyst Downgrades in December 2024

GuruFocus.com12-23 18:07

December 2024 seems to be the month of skepticism for Biogen Inc (NASDAQ:BIIB), as this biotechnology company focusing on neurological and neurodegenerative diseases has received multiple downgrades ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493709732?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9qrU.SNfxlnRxq5ha3cTPQ--~B/aD05OTt3PTI5NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/3dacfff8652bb48efcbb9dbda59a319b","is_english":true,"pubTime":"2024-12-23 18:07","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2493709732","market":"us","top_or_hot":-1,"title":"Biogen Faces Multiple Analyst Downgrades in December 2024","media":"GuruFocus.com","content":"<div>\n<p>December 2024 seems to be the month of skepticism for Biogen Inc (NASDAQ:BIIB), as this biotechnology company focusing on neurological and neurodegenerative diseases has received multiple downgrades ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biogen-faces-multiple-analyst-downgrades-100737007.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Faces Multiple Analyst Downgrades in December 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Faces Multiple Analyst Downgrades in December 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/biogen-faces-multiple-analyst-downgrades-100737007.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>December 2024 seems to be the month of skepticism for Biogen Inc (NASDAQ:BIIB), as this biotechnology company focusing on neurological and neurodegenerative diseases has received multiple downgrades ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biogen-faces-multiple-analyst-downgrades-100737007.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"https://finance.yahoo.com/news/biogen-faces-multiple-analyst-downgrades-100737007.html","article_id":"2493709732","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9qrU.SNfxlnRxq5ha3cTPQ--~B/aD05OTt3PTI5NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/3dacfff8652bb48efcbb9dbda59a319b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493709732","pubTimestamp":1734948457,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"December 2024 seems to be the month of skepticism for Biogen Inc , as this biotechnology company focusing on neurological and neurodegenerative diseases has received multiple downgrades from analysts this month on numerous reasons.This month, investment company Jeffries lowered their price target for Biogen from $250 to $180 and downgraded the stock to Hold from initially Buy rating. Jeffries stated that they concerned over modest sales growth, a lackluster pipeline, and massive revenue declines outlook in the next 5 years.Biogen is now relying on royalties from Ocrevus and the contribution from that could reduce up to 50% by 2030 due to biosimilar competition, potentially imposing a 20-30% reduction to Biogen's total revenue.BMO Capital also said that they expect slower revenue growth for Biogen's Alzheimer drug Leqembi, weaker growth in its rare disease pipeline and decline in multiple sclerosis drug sales. Thus, cut their price target to $164 only and downgraded Biogen to market per","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司"},"translate_title":"Biogen将于2024年12月面临多项分析师下调评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1},"content_text":"December 2024 seems to be the month of skepticism for Biogen Inc (NASDAQ:BIIB), as this biotechnology company focusing on neurological and neurodegenerative diseases has received multiple downgrades from analysts this month on numerous reasons.\nThis month, investment company Jeffries lowered their price target for Biogen from $250 to $180 and downgraded the stock to Hold from initially Buy rating. Jeffries stated that they concerned over modest sales growth, a lackluster pipeline, and massive revenue declines outlook in the next 5 years. \n\nWarning! GuruFocus has detected 6 Warning Signs with BIIB.\n\nBiogen is now relying on royalties from Ocrevus and the contribution from that could reduce up to 50% by 2030 due to biosimilar competition, potentially imposing a 20-30% reduction to Biogen's total revenue. \nBMO Capital also said that they expect slower revenue growth for Biogen's Alzheimer drug Leqembi, weaker growth in its rare disease pipeline and decline in multiple sclerosis drug sales. Thus, cut their price target to $164 only and downgraded Biogen to market perform or Hold from initially outperform.\nIn another report this month also, investment company Stifel Nicolaus also downgraded Biogen to Hold and lowered their price target for Biogen to $175. Same story for BofA that reinstated its coverage in December witha Neutral rating for Biogen with price target of $178.\nBiogen Current Condition\nBiogen's Alzheimer's drug Leqembi has been FDA-approved but the adoption is relatively slow as only about 2,000 patients in the U.S. that used Leqembi in the seven months following the approval. \nPatients need to undergo several tests like brain scans or spinal taps before they can access the Alzheimer drug. The complicated process prior to the drug use makes the drug adoption slow and therefore it is hard to project the revenue growth from this newly approved Alzheimer drug Leqembi. \nAnalysts see no catalysts for Biogen in near future, but the downside is limited, so Biogen is still worth tracking. This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493709732"}